These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 25115382)

  • 1. HDAC inhibitors and immunotherapy; a double edged sword?
    Kroesen M; Gielen P; Brok IC; Armandari I; Hoogerbrugge PM; Adema GJ
    Oncotarget; 2014 Aug; 5(16):6558-72. PubMed ID: 25115382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.
    Ramaiah MJ; Tangutur AD; Manyam RR
    Life Sci; 2021 Jul; 277():119504. PubMed ID: 33872660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDAC inhibitors as epigenetic regulators for cancer immunotherapy.
    Conte M; De Palma R; Altucci L
    Int J Biochem Cell Biol; 2018 May; 98():65-74. PubMed ID: 29535070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone Deacetylase Inhibitors in Cancer Therapy.
    Sun Y; Sun Y; Yue S; Wang Y; Lu F
    Curr Top Med Chem; 2018; 18(28):2420-2428. PubMed ID: 30526462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics.
    McClure JJ; Li X; Chou CJ
    Adv Cancer Res; 2018; 138():183-211. PubMed ID: 29551127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of histone deacetylases and their inhibitors in cancer biology and treatment.
    Beumer JH; Tawbi H
    Curr Clin Pharmacol; 2010 Aug; 5(3):196-208. PubMed ID: 20406169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Overview of HDAC Inhibitors and their Synthetic Routes.
    Peng X; Liao G; Sun P; Yu Z; Chen J
    Curr Top Med Chem; 2019; 19(12):1005-1040. PubMed ID: 30827245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
    Li Y; Seto E
    Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.
    Park J; Thomas S; Munster PN
    Epigenomics; 2015; 7(4):641-52. PubMed ID: 26111034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Epigenetic mechanisms and alcohol use disorders: a potential therapeutic target].
    Legastelois R; Jeanblanc J; Vilpoux C; Bourguet E; Naassila M
    Biol Aujourdhui; 2017; 211(1):83-91. PubMed ID: 28682229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitors in cancer therapy.
    Lane AA; Chabner BA
    J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of histone deacetylase inhibitors for cancer treatment.
    Marchion D; Münster P
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in histone deacetylase targeted cancer therapy.
    Hoshino I; Matsubara H
    Surg Today; 2010 Sep; 40(9):809-15. PubMed ID: 20740342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitors in cancer therapy. A review.
    Hrabeta J; Stiborova M; Adam V; Kizek R; Eckschlager T
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Jun; 158(2):161-9. PubMed ID: 24263215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present).
    Zhao C; Dong H; Xu Q; Zhang Y
    Expert Opin Ther Pat; 2020 Apr; 30(4):263-274. PubMed ID: 32008402
    [No Abstract]   [Full Text] [Related]  

  • 16. Histone deacetylase inhibitors and cancer: from cell biology to the clinic.
    Hess-Stumpp H
    Eur J Cell Biol; 2005 Mar; 84(2-3):109-21. PubMed ID: 15819394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone Deacetylase Inhibitors in Tumor Immunotherapy.
    Zhao LM; Zhang JH
    Curr Med Chem; 2019; 26(17):2990-3008. PubMed ID: 28762309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications.
    Li Z; Zhu WG
    Int J Biol Sci; 2014; 10(7):757-70. PubMed ID: 25013383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis.
    Shankar S; Srivastava RK
    Adv Exp Med Biol; 2008; 615():261-98. PubMed ID: 18437899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications.
    Khan O; La Thangue NB
    Immunol Cell Biol; 2012 Jan; 90(1):85-94. PubMed ID: 22124371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.